We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Diversey Holdings, Ltd. (“Diversey” or the“Company”) (NASDAQ: DSEY), in connection with the proposed acquisition of the Company by Solenis. Under the terms of the merger agreement, the Company’s shareholders (other than shareholders affiliated with Bain Capital Private Equity (“Bain Capital”)) will receive $8.40 in cash for each share of Diversey common stock owned. Bain Capital will receive $7.84 per share in cash and will rollover a portion of its shares of Diversey into an affiliate of Solenis in exchange for common and preferred units of such affiliate. The transaction is valued at approximately $4.6 billion.
Weiss Law is investigating whether (i) Diversey’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $8.40 per share merger consideration adequately compensates Diversey’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, at least one analyst set a price target for the Company of $9 per share, $0.60 above the per-share merger consideration.
September 26, 2023
We are investigating possible breaches of fiduciary duty and violations of the federal securities laws by, among others, the Board of Directors and senior officers of Origin Materials, Inc. (NASDAQ: ORGN) (“Origin” or the “Company”), concerning the Company’s business, operations, and prospects surrounding the construction of the Origin 2 commercial plant.
September 14, 2023
Weiss Law announces that on September 13, 2023, they filed a class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences Ltd. et al. Case 1:23-cv-08097, on behalf of a class (“Class”) of individuals and entities that held common stock of Myovant Sciences, Ltd. (“Myovant”) as of the close of business on January 20, 2023 (“Class Period”), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and Securities and Exchange Commission Rule 14a-9, in connection with the acquisition of Myovant Sciences, Ltd. by Sumitovant Biopharma Ltd. for an unfair price.
September 11, 2023
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hostess Brands, Inc. (“Hostess” or the “Company”) (NASDAQ: TWNK), in connection with its acquisition by The J. M. Smucker Company (NYSE: SJM) (“Smucker”) via tender offer.